Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Analysis of Mesenchymal Stromal Cell Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study

Castello, Laura M., MSc*; Leone, Marco, BSc*; Adamini, Aloe, MSc*; Castiglia, Sara, MSc*; Mareschi, Katia, MSc*,†; Ferrero, Ivana, MSc*,†; Marco, De Gobbi, MD; Carnevale-Schianca, Fabrizio, MD§; Fagioli, Franca, MD*; Berger, Massimo, MD, PhD*

Journal of Pediatric Hematology/Oncology: November 2018 - Volume 40 - Issue 8 - p e486–e489
doi: 10.1097/MPH.0000000000001305
Online Articles: Original Articles

The mesenchymal stem cell (MSC) role after allogeneic hematopoietic stem cell transplantation (HSCT) is still a matter of debate; in particular, MSC engraftment in recipient bone marrow (BM) is unclear. A total of 46 patients were analyzed for MSC and hemopoietic stem cell engraftment after HSCT. The majority of patients had the BM as the stem cell source, and acute leukemia was the main indication for HSCT. Mesenchymal and hematopoietic stem cell chimerism analysis was carried out through specific polymorphic tandemly repeated regions. All patients reached complete donor engraftment; no evidence of donor-derived MSC engraftment was noted. Our data indicate that MSCs after HSCT remain of recipient origin despite the following: (i) myeloablative conditioning; (ii) the stem cell source; (iii) the interval from HSCT to BM analysis; (iv) the underlying disease before HSCT; and (v) the patients’ or the donors’ age at HSCT.

*Department of Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, City of Science and Health of Turin, Regina Margherita Children’s Hospital, Turin

Departments of Public Health and Pediatrics

Clinical and Biological Science, San Luigi Gonzaga Hospital, University of Turin, Orbassano

§Institute for Cancer Research and Treatment-FPO, IRCCS, Candiolo, Italy

L.M.C. and M.L. contributed equally.

The authors declare no conflict of interest.

Reprints: Massimo Berger, MD, PhD, Department of Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, City of Science and Health of Turin, Regina Margherita Children’s Hospital, Turin 10126, Italy (e-mail: massimo.berger@unito.it).

Received November 3, 2017

Accepted August 7, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.